Major trial aims to halt MS disability progression
NCT ID NCT07299019
Summary
This large, late-stage study is testing whether the drug orelabrutinib can slow or stop the worsening of disability in people with a specific form of progressive multiple sclerosis (MS) who have not had recent relapses. About 990 participants worldwide will receive either the study drug or a placebo for 1 to 5 years to see which group experiences less decline in walking, hand function, and thinking. The main goal is to see if the drug can delay the progression of physical disability confirmed over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.